The field of cancer care has evolved over the past 20 years with the development of more aggressive cancer screening programs, improvement in diagnostic testing and more effective treatment options, including the incorporation of novel targeted therapies. As a result, despite growing extent of cancer diagnosis, the rate of successful treatment of cancer is even larger. Cancer death rates are gradually declining while cancer survivorship is steadily rising. These benefits are offset by short and long term adverse effects. Among them, cardiovascular toxicity has become a leading cause for late morbidity and mortality. While conventional chemotherapy has been known for decades to induce detrimental effects on the heart and peripheral vasculature, the novel agents might also have harmful off-target consequences.